Biotechnology Innovations In Medicine

Researchers at Johns Hopkins University have created a revolutionary protein “switch” that tricks cancer cells into manufacturing their own chemotherapy drugs, causing them to self-destruct while sparing healthy cells. Instead of delivering drugs directly to cancer cells, this method uses a harmless “prodrug” that only becomes activated inside cancer cells when the switch detects specific cancer markers. The switch is made by combining two proteins: one that senses cancer markers and another from yeast that converts the inactive prodrug into a potent cancer-killing drug. When the switch detects cancer, it activates the drug inside that cell, turning the cancer cell into a drug factory that destroys itself. To work, the switch must enter cancer cells either by delivering the protein itself or by inserting the gene that makes the protein, allowing the cancer cell’s own machinery to produce the switch. Afterward, patients receive the inactive chemotherapy prodrug, which becomes activated only inside cancer cells. This new approach focuses on producing the drug inside cancer cells rather than just delivering it to them, which could kill more cancer cells while reducing harmful side effects on healthy tissue. Lab tests on human colon and breast cancer cells have shown promise, and animal testing is expected to start within a year. While still early, this technique offers a radically different way to attack cancer. #PNAS #RMScienceTechInvest

We sought to make proteins both potent and fast. We used #proteindesign to design precise control over protein interaction lifetimes, enabling us to construct rapid-response circuits, biosensors, and switchable cytokines. Now published at Nature Magazine! https://lnkd.in/gdZXETwN High affinity protein binders often have potent biological effects on their targets. But their long interaction half-lives limit their response rates to direct competition, so it has been difficult to design high-affinity systems that can also be rapidly switched off. We designed a switch protein that is strongly driven to change conformation upon binding an effector, and can attach this protein to almost any binder such that, when the effector is added, the resulting conformational change forces the complex into a high-energy strained state, causing dissociation of the binder from its target to dramatically accelerate! We applied this facilitated dissociation to control biological systems with high temporal resolution. Interleukin-2 (IL-2) has been explored for decades in cancer immunotherapy. It potently activates the immune system to attack tumors, but inadvertently also healthy cells, causing toxicity and a narrow therapeutic window. Since IL-2 binds its receptors tightly, it is difficult to quickly shut off its activity. We designed switchable IL-2-like cytokines that can be rapidly dissociated from their receptors to terminate signaling. By stimulating with cytokine and later adding effector, the duration of signaling can be controlled, providing another lever of therapeutic control beyond dose. Christoph showed that adding the effector completely deactivated signaling complexes on the cell surface within 10 seconds, immediately stopping STAT5 signaling. Yang showed that transient IL-2 stimulation decouples fast downstream responses (like cell survival) from slow ones (like cell proliferation), and using RNA-seq showed that this applies to a broad range of cell functions. More generally, the residence time of ligands on their receptors is thought to modulate the downstream cell response, but this is difficult to study. This work shows how facilitated dissociation can be applied to explore this outstanding biological question. Designing the kinetics of protein change is challenging because it requires the design of both ground and excited intermediate states. This work shows that switching moderately sized steric clashes is a straightforward way to introduce strain to design excited intermediates. Finally, this work shows how introducing flexibility into designed protein systems can reduce energy barriers, enhancing transition rates. We are excited for the potential applications of this work. If you have ideas that could benefit from designed facilitated dissociation and would like to discuss or collaborate, please reach out! Collaborating with everyone on the team really took this project to the next level—thanks to all of you!

A technical breakthrough from Australia is able to track DynamicMicroData (DMD), the basis for Gen-3 Wearables, a major shift in trackers which we predicted recently. A team from the University of New South Wales has created tiny ultra-thin cantilevered sensors that can detect multiple physiological mechano-acoustic signals over an outstanding bandwidth of 15.5 octaves, yes octaves! These sensors are integrated into small adhesive wearables. With a power demand of under 5mW they are able to continuously capture subtle vibrations produced by the heart, lungs, blood flow, an even vocal chords. An AI layer allows these signals to be segregated and analyzed for clinical decision-making. The high sensor bandwidth enables the device to detect signals that are way beyond the capability of today’s trackers. The ability to acquire DMD for example, allows the wearable to ‘listen’ to heart-valves opening and closing, or track the transitions between sleep stages which are rich in information related to central nervous system functionality. As just one example, the attached chart shows details of breathing transitions which are important in diagnosing the occurrence and causes of sleep disturbed breathing, a field of great interest to our team and one which is ripe for new innovations in both diagnoses and therapies. This Australian development is a clear marker for the future of healthcare and a sign that major changes are likely to come faster than originally thought. We can anticipate a time when our key health markers are tracked continuously enabling a shift to early preventative care from late symptom treatment. For those wanting to learn more, access the full Nature report. You will find the future shining bright!

As our Drug Hunter team was compiling the November Molecule Roundup, one molecule that really caught our attention was Compound 4—a mutant-selective, salicylaldehyde-based covalent inhibitor designed to target the AKT1 (E17K) oncogenic mutation. This discovery, reported in collaboration between Jack Taunton’s group at University of California, San Francisco and Terremoto Biosciences in Nature Magazine, addresses a mutation frequently observed in solid tumors, where it drives persistent oncogenic signaling via constitutive membrane localization. What makes Compound 4 stand out to me is its design strategy. Unlike traditional pan-AKT inhibitors, which are often plagued by dose-limiting hyperglycemia, Compound 4 leverages a unique allosteric, lysine-targeted mechanism to achieve exceptional selectivity for AKT1 (E17K) over wild-type AKT isoforms. Structural analysis uncovered an unexpected twist: the salicylaldimine adduct, formed with the mutant lysine, recruits endogenous Zn²⁺. This zinc ion coordinates with two proximal cysteines in the kinase activation loop, resulting in sustained inhibition of AKT1 (E17K) while leaving wild-type AKT isoforms largely unaffected. The outcome? Robust anti-tumor efficacy in AKT1 (E17K) xenograft models, without inducing the hyperglycemia often seen with traditional inhibitors. What excites me most is the broader potential of this approach. The chelation-enhanced binding mechanism suggests that this strategy could be extended to other proteins with lysines near metal-binding regions, such as metalloenzymes and zinc fingers. This could open entirely new avenues for targeting previously elusive protein classes. What other targets do you think could benefit from this chelation-enhanced strategy? Explore our full November Molecule Roundup here: https://lnkd.in/e6Jsny6A And stay tuned—we’re finalizing our December molecules now!

🛏️ Revolutionizing Sleep Monitoring: From Wristbands to Real Biomarkers Traditional wearables fall short when it comes to sleep diagnostics—they miss direct respiratory signals, which are vital for identifying sleep stages and disorders like sleep apnea. This new research introduces a low-power, skin-integrated mechanoacoustic (LMA) sensor that changes the game. It doesn't just guess your sleep from motion—it listens to your breath and heartbeat. https://lnkd.in/g_yZW69p 🔬 Key innovations: - Multimodal sensor captures respiratory rate, heart rate variability (HRV), respiration rate variability (RRV), body movement, and more. -Paired with LMA-SleepNet, an interpretable machine learning model that detects sleep stages and apnea events with clinical-grade accuracy. - Uses physiology-based features like baroreflex and muscle tone—giving deeper insights than motion-based trackers. Outperforms other wearables in real-world accuracy. 📊 Why this matters: - Directly measures respiration—a core but missing biomarker in most wearables. - Enables continuous, personalized, and explainable sleep tracking in the home or clinic. - Opens doors for smart OSA detection, snoring tracking, and even future on-body therapeutic interventions. 💡 Bonus: Real-time UTC synchronization allows scalable multi-sensor studies across environments and populations. 🔁 This is more than a device—it’s a complete hardware-software platform for next-gen sleep and health monitoring, with huge potential for precision healthcare, chronic disease management, and behavioral science. 👀 Sleep isn’t just rest—it’s integrated physiological data. And now, we can measure it better than ever. #SleepScience #WearableTech #DigitalHealth #MachineLearning #SleepApnea #RespiratoryHealth #PrecisionMedicine #Bioengineering #HealthTech #HRV #RRV

Sleep deprivation may soon be detectable from a saliva sample. A new study published in the Journal of Proteome Research used untargeted oral-fluid metabolomics and machine learning to identify a "sleepiness fingerprint" in saliva following acute total sleep deprivation. In a randomized, controlled crossover trial, 20 healthy young men completed three conditions: one night of total sleep deprivation, four nights of sleep restriction to 6 hours, and a control condition of 8 hours of sleep. Saliva was collected at multiple time points and analyzed using liquid chromatography-mass spectrometry. The key finding: a logistic regression model trained on just 12 salivary metabolite features could classify acute sleep deprivation with an F0.5 score of 0.90, without requiring a baseline sample from the same individual. The fingerprint was most detectable in morning and midday samples. Chronic sleep restriction to 6 hours, by contrast, did not produce a comparable salivary signature, suggesting the metabolic response is specific to acute total sleep loss rather than cumulative restriction. The practical implication the authors are pursuing is a roadside test for dangerous sleepiness, analogous to a breathalyzer but for sleep deprivation. A large-scale international validation is already underway, expanding to 1,000+ samples across shift workers, women, and frequent drivers. This is critical, b/c this first study was in 20 young men under controlled laboratory conditions. For those of us in clinical research and supplement science, this is a useful methodological development on two fronts. First, it validates saliva as a viable matrix for detecting acute physiological states, not just chronic biomarkers. Second, the reference-free ML classification approach (no individual baseline required) is the kind of design feature that makes a test translatable to real-world settings. Worth watching as the validation data come in. https://lnkd.in/eENx_rFQ #SleepScience #Metabolomics #ClinicalResearch #Biomarkers #SportsScience

Researchers in Japan have built a novel delivery system that helps powerful cancer targeting antibodies reach parts of tumor cells they normally cannot access. Traditional antibody therapies latch onto markers on the surface of cancer cells, but many of the most dangerous cancer signals are buried deep inside the cell. These engineered nanocarriers combine natural polyphenols with metal ions and a biocompatible polymer to form particles about thirty nanometers wide that can enter tumor cells and then burst open internal compartments, releasing antibodies right where they are needed. Once injected into the bloodstream, the nanomachines travel to tumors and get taken up into tiny bubbles inside cells called endosomes. The clever design uses a metal phenolic network that triggers a buffer effect inside these endosomes, making them burst and free the antibody cargo. In mouse models of aggressive breast cancer, delivering an antibody that targets a protein involved in tumor spread led to dramatic tumor shrinkage compared with untreated animals. This approach overcomes a major hurdle in cancer immunotherapy: getting large protein drugs past cellular barriers and deep into the heart of cancer cells. By enabling antibodies to reach hidden intracellular targets, the system may broaden the range of cancers that antibody based therapies can effectively treat and inspire new designs for smarter nanomedicines. Research Paper 📄 DOI: 10.1016/j.jconrel.2025.113929

Cancer Cells Turned Against Themselves: A Revolutionary Therapy Emerges Scientists Engineer Protein Switch to Create Self-Destructing Tumors at Johns Hopkins 🧬🔥 In a stunning breakthrough, researchers at Johns Hopkins University have developed an innovative cancer treatment that flips the script on tumors. Instead of conventional chemotherapy which often harms healthy cells this therapy uses a smart protein “switch” to reprogram cancer cells into factories that produce and activate their own lethal drugs. This approach targets tumors with remarkable precision, sparing normal tissue and minimizing side effects. The secret lies in a two-part protein designed to identify cancer-specific markers and unleash its power only inside malignant cells. One segment homes in on unique cancer markers, while the other borrowed from yeast activates an otherwise harmless chemotherapy compound (a prodrug) by converting it into a potent drug inside the tumor. This clever mechanism turns cancer cells into their own worst enemies, effectively triggering self-destruction from within. This groundbreaking therapy represents a major shift in cancer treatment, moving from broad attacks on cells to precision, self-targeting approaches. With further development, this method could revolutionize how we combat cancer offering patients safer, more effective options and a new beacon of hope in the fight against one of humanity’s deadliest diseases

Savage et al. offers a massive leap forward in the fight against glioblastoma and opens a new paradigm for solid tumor attack. For years, CAR-T cell therapies have revolutionized blood cancer treatments, but they have repeatedly hit a wall with solid brain tumors. The reason? Glioblastoma isn’t just a cluster of cancer cells; it's a deeply protected "tumor-immune ecosystem." The tumor recruits the body’s own macrophages and reprograms them to act as a shield, rendering traditional treatments ineffective. The Breakthrough: A Two-Pronged Strike 🎯 Instead of focusing solely on the cancer cells, the team utilized a multi-omic discovery platform to identify a unique protein called GPNMB. What makes GPNMB special is that it is heavily expressed on both the glioblastoma tumor cells and the immunosuppressive macrophages shielding them. By engineering CAR-T cells to specifically target GPNMB, they created a dual-action therapeutic strike force that: Destroys the cancer cells directly. Collapses the immune shield by clearing out the corrupted macrophages. In preclinical models grown directly from human patient tumors, this dual-targeting design completely eradicated detectable malignancies, yielding long-term, disease-free survival. This research shifts the paradigm for how we approach aggressive, myeloid-rich solid tumors - which is by far the majority of all tumors! By treating the cancer and its microenvironment as a single coupled system, we open up entirely new blueprints for antigen selection and therapy design. While more research is required before moving into human clinical trials, this marks a great step toward. #CancerResearch #Immunotherapy #Biotech #CAR_TCell #NeuroOncology #Innovation #Medicine #Macrophage #TME #Immunology https://lnkd.in/gWdMkU9v

Researchers have created a bio engineered molecule that shows promise in eliminating cancer cells while also turning on the body’s own immune defenses. In laboratory experiments, the molecule was designed to seek out tumor cells and trigger processes that lead to their destruction. At the same time, it stimulates key immune pathways that help the body recognize and attack cancer more effectively, creating a two-pronged effect that goes beyond simply killing malignant cells. This approach aims to solve two major challenges in cancer treatment. Many therapies can reduce tumor size but leave the immune system unengaged, allowing residual or recurring cells to persist. By contrast, the engineered molecule not only induces cancer cell death but also sends alerts to immune cells. These signals encourage immune surveillance and long term response against cancer markers, potentially reducing the chance of disease resurgence. In the lab setting, the combined effects produced significant cancer cell death along with activation of immune signaling proteins and immune cell recruitment. While these results come from preclinical studies, they reveal how carefully designed molecules can coordinate direct tumor targeting with immune activation. The findings may inform future therapeutic strategies that harness both targeted cytotoxicity and the body’s natural defenses. Research Paper 📄 DOI: 10.1136/jitc-2024-011198